

one centre one solution

patients

commercial CRO

therapeutic experts



patient studies at
richmond pharmacology
integrated trials centre

↳ a new opportunity in patient studies

Due to the EU Clinical Trials Directive, traditional distinctions between phase I and II have become blurred and the scope for Phase I studies in patients is now greatly enhanced. This offers you, the sponsor, unprecedented opportunity for more efficient and rapid progress through your Early Phase trials.

Our integrated solution: Hospital based with optional Phase I control benefits

Richmond Pharmacology's innovative new set-up enables clients to take advantage of world class therapeutic consultancy with the added control benefits of dedicated, full service in-patient research facilities. This Integrated Trials Centre provides in and outpatient studies from within 2 acute NHS Teaching Hospitals. Our set-up has been developed to operate as an SMO or CRO for Patient Studies, and Richmond Pharmacology manage these trials with the proficiency of our Phase I heritage. This integrated solution offers you direct, efficient and swift delivery of any Early Phase study.



St George's & Mayday Hospitals

Single point access to consultants and patients

Richmond Pharmacology is the UK's first CRO to own dedicated clinical research facilities within 2 acute NHS teaching Hospitals – our facilities in St George's University of London, St George's Hospital and Mayday University Hospital provide the ideal setting for patient studies.

These locations allow us immediate access to world class experts and consultants across an extensive range of therapeutic areas, including: cardiology, dermatology, neurology, oncology, renal, respiratory and urology to mention just a few. We have easy access to a potential patient population in excess of 4 million people within the immediate catchment area of our two hospitals alone.

We act as a single point of interface between the sponsor and the clinicians, empowering our clients to manage the trial to their requirements.

In and Out-Patient studies

Patient studies in a Phase I facility

Richmond Pharmacology conducts patient studies dependent on the control requirements of your protocol, and we are able to perform even the most complex studies, thanks to our innovative dedicated research facilities.

With 100 research beds based within our dedicated, access controlled facilities, we conduct in-patient studies within an existing Phase I environment, and deliver a premium standard through state-of-the-art technology and pharmacological proficiency. Our acute NHS facilities include dedicated, in-house laboratories, pharmacies and kitchens. Our chef prepares meals tailored to study requirements and our volunteers stay in one of our spacious open plan wards, complete with internet access, DVD's, magazines and games consoles and a relaxation lounge.

We also provide out-patient studies for protocols with less in-house control requirements. This flexibility affords you the option to combine in and out-patient studies to test a greater number of parameters in one trial. Our staff look after trial participants' every need during their visit.

Our GMP-licensed pharmacies can handle any study and supports many trials running within St George's and Mayday hospitals.

Phase I, Phase II, or Early Phase?

Our integrated centre delivers direct solutions

We have combined the best of traditional Phase I pharmacological proficiency with the best clinical expertise through on-site access to patients, consultants and in-patient facilities.

Our integrated setting overcomes multi-centre logistical and accuracy issues, so you benefit from a focused study managed directly through one provider. This means more readily available expert advice, and accurate data, eliminating the need to include additional subjects to compensate for between centre variability. This helps your investment become more efficient and minimises time spent in the Early Phases.

We deliver traditionally defined pharmacology and patient studies, and, of course, Phase I patient studies. This flexible approach enables you to select the most appropriate solution for your protocol and allows fast access to efficacy data in relevant patient populations.

Whichever approach you choose, you will benefit from this efficient, centralised model to get the strongest return on your Early Phase investment.





RICHMOND PHARMACOLOGY LTD

Directors:

Dr Jörg Täubel MD MFPM

Dr Radivoj Arezina MD MSc

Dr Ulrike Lorch MD MFPM FRCA

Mr P Magness FCA

Mr L Levine

Mr M Z Levine

Prof. BNC Prichard FRCP FACC FESC FFPM

Richmond Pharmacology Ltd
St George's University London
Cranmer Terrace, Tooting
London, SW17 0RE

T +44 (0)20 8664 5200

F +44 (0)20 8664 5201

E info@richmondpharmacology.com

All information correct at time of printing